Literature DB >> 16005038

In vivo and in vitro anti-androgenic effects of DE-71, a commercial polybrominated diphenyl ether (PBDE) mixture.

T E Stoker1, R L Cooper, C S Lambright, V S Wilson, J Furr, L E Gray.   

Abstract

PBDEs have been synthesized in large quantities as flame retardants for commercial products, such as electronic equipment and textiles. The rising in levels of PBDEs in tissues in wildlife species and in human milk and plasma samples over the past several years have raised concerns about possible health effects. Recently, we showed that the PBDE mixture, DE-71, delayed puberty and suppressed the growth of androgen-dependent tissues in male Wistar rat following a peri-pubertal exposure. These effects suggested that DE-71 may be either inducing steroid hormone metabolism or acting as an androgen receptor (AR) antagonist. To elucidate the potential anti-androgenic effects of this mixture, we evaluated DE-71 in several in vivo assays, which are responsive to alterations in androgen activity. In a pubertal exposure study designed to further evaluate the delay in preputial separation (PPS), we observed a dose-dependent delay in PPS with 60 and 120 mg/kg/day of DE-71 (4 and 5 days) and a corresponding suppression of ventral prostate (VP) and seminal vesicle growth at both doses. Adult males exposed to 60 mg/kg DE-71 for 3 days resulted in a significant increase in luteinizing hormone and a non-significant increase in testosterone, androstenedione and estrone. DE-71 also tested positive for anti-androgenic activity in an immature rat Hershberger assay, with decreases in mean VP and seminal vesicle weight following doses of 30-240 mg/kg. DE-71 and the individual BDE congeners which comprise the mixture (BDE-47, -99, -100, -153, -154) were also evaluated in vitro. First, AR binding was evaluated in a competitive binding assay using rat VP cytosol. In addition, we evaluated gene activation in a transcriptional activation assay using the MDA-kb2 cell line which contains an endogenous human AR and a transfected luciferase reporter. DE-71 and BDE-100 (2, 4, 6-pentaBDE) both inhibited AR binding, with IC50s of approximately 5 microM. In addition, DE-71 and two of the congeners (BDE-100 and BDE-47) inhibited DHT-induced transcriptional activation. The pattern of inhibition shown in the double-reciprocal plot for BDE-100 and the linear slope replot confirmed that the in vitro mechanism is pure competitive inhibition, with a inhibition constant (Ki) of 1 microM. The delay in puberty in the male rat and decreased growth of androgen-dependent tissues observed previously following exposure to DE-71 were likely due to this inhibition of AR binding by several of the congeners which make up this mixture.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16005038     DOI: 10.1016/j.taap.2005.05.010

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  42 in total

1.  Association of prenatal and childhood PBDE exposure with timing of puberty in boys and girls.

Authors:  Kim G Harley; Stephen A Rauch; Jonathan Chevrier; Katherine Kogut; Kimberly L Parra; Celina Trujillo; Robert H Lustig; Louise C Greenspan; Andreas Sjödin; Asa Bradman; Brenda Eskenazi
Journal:  Environ Int       Date:  2017-01-12       Impact factor: 9.621

2.  Perinatal exposure to low-dose DE-71 increases serum thyroid hormones and gonadal osteopontin gene expression.

Authors:  Charles A Blake; George L McCoy; Yvonne Y Hui; Holly A LaVoie
Journal:  Exp Biol Med (Maywood)       Date:  2011-03-02

Review 3.  A perspective on the potential risks of emerging contaminants to human and environmental health.

Authors:  Lílian Cristina Pereira; Alecsandra Oliveira de Souza; Mariana Furio Franco Bernardes; Murilo Pazin; Maria Júlia Tasso; Paulo Henrique Pereira; Daniel Junqueira Dorta
Journal:  Environ Sci Pollut Res Int       Date:  2015-07-24       Impact factor: 4.223

4.  Male reproductive disorders, diseases, and costs of exposure to endocrine-disrupting chemicals in the European Union.

Authors:  Russ Hauser; Niels E Skakkebaek; Ulla Hass; Jorma Toppari; Anders Juul; Anna Maria Andersson; Andreas Kortenkamp; Jerrold J Heindel; Leonardo Trasande
Journal:  J Clin Endocrinol Metab       Date:  2015-03-05       Impact factor: 5.958

5.  Serum polybrominated diphenyl ether (PBDE) concentrations in relation to biomarkers of oxidative stress and inflammation: The National Health and Nutrition Examination Survey 2003-2004.

Authors:  Ye Yuan; John D Meeker; Kelly K Ferguson
Journal:  Sci Total Environ       Date:  2016-10-14       Impact factor: 7.963

6.  Effects of fluoro substitution on 4-bromodiphenyl ether (PBDE 3).

Authors:  J Klösener; D C Swenson; L W Robertson; G Luthe
Journal:  Acta Crystallogr B       Date:  2008-01-17

Review 7.  Fifteen years after "Wingspread"--environmental endocrine disrupters and human and wildlife health: where we are today and where we need to go.

Authors:  Andrew K Hotchkiss; Cynthia V Rider; Chad R Blystone; Vickie S Wilson; Phillip C Hartig; Gerald T Ankley; Paul M Foster; Clark L Gray; L Earl Gray
Journal:  Toxicol Sci       Date:  2008-02-16       Impact factor: 4.849

8.  Polybrominated diphenyl ether (PBDE) concentrations in house dust are related to hormone levels in men.

Authors:  John D Meeker; Paula I Johnson; David Camann; Russ Hauser
Journal:  Sci Total Environ       Date:  2009-02-10       Impact factor: 7.963

9.  Involvement of reactive oxygen species in brominated diphenyl ether-47-induced inflammatory cytokine release from human extravillous trophoblasts in vitro.

Authors:  Hae-Ryung Park; Patricia W Kamau; Rita Loch-Caruso
Journal:  Toxicol Appl Pharmacol       Date:  2013-12-01       Impact factor: 4.219

10.  Nuclear hormone receptor activity of polybrominated diphenyl ethers and their hydroxylated and methoxylated metabolites in transactivation assays using Chinese hamster ovary cells.

Authors:  Hiroyuki Kojima; Shinji Takeuchi; Naoto Uramaru; Kazumi Sugihara; Takahiko Yoshida; Shigeyuki Kitamura
Journal:  Environ Health Perspect       Date:  2009-04-28       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.